↑ 薬物リストへ　← 戻る

High-dose regn4461    (DrugBank: -)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
265脂肪萎縮症1

265. 脂肪萎縮症　［臨床試験数：109，薬物数：164（DrugBank：59），標的遺伝子数：26，標的パスウェイ数：94］
Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 109 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04159415
(ClinicalTrials.gov)		January 7, 20207/11/2019Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyA Randomized, Double-Blind, Placebo-Controlled Study of REGN4461, a Leptin Receptor Agonist Antibody, in Patients With Generalized LipodystrophyGeneralized LipodystrophyDrug: Placebo;Drug: Low-Dose REGN4461;Drug: High-dose REGN4461Regeneron PharmaceuticalsNULLActive, not recruiting12 YearsN/AAll26Phase 2United States